產(chǎn)品[
CRL-1997 HPAF-II 人胰腺癌細(xì)胞
]資料
如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
CRL-1997 HPAF-II 人胰腺癌細(xì)胞
產(chǎn)品型號(hào):
CRL-1997
產(chǎn)品廠商:
美國(guó)標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無(wú)相關(guān)文檔
簡(jiǎn)單介紹
CRL-1997 HPAF-II 人胰腺癌細(xì)胞,原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種;細(xì)胞庫(kù)管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件!
CRL-1997 HPAF-II 人胰腺癌細(xì)胞
的詳細(xì)介紹
CRL-1997 HPAF-II 人胰腺癌細(xì)胞
|
|
CRL-1997?
|
|
$329.00
|
|
|
HPAF-II
|
|
|
RS Metzgar
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: pancreas
Disease: adenocarcinoma
|
|
|
mucin
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Yes
|
|
|
Blood Type A; Rh-; HLA A1, A10 (W34), B8, W22, Cw3
|
|
|
Amelogenin: X
CSF1PO: 10,11
D13S317: 12
D16S539: 11,13
D5S818: 11,13
D7S820: 10,13
F13A01: 5,17
F13B: 8,10
FESFPS: 11,12
LPL: 10
THO1: 9
TPOX: 8
vWA: 17
|
|
|
44 years
|
|
|
male
|
|
|
Caucasian
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
|
Protocol:
-
Remove and discard culture medium.
-
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
-
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
-
Add appropriate aliquots of the cell suspension to new culture vessels.
-
Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: 2 to 3 times per week
|
|
|
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
|
|
|
21871: . Monoclonal antibodies in cancer. Clifton, NJ: Humana Press; 1985.
21882: . Monoclonal antibodies and cancer therapy. New York: Liss; 1985.
21891: . Immunity to cancer II. New York: Liss; 1989.
22431: Metzgar RS, et al. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res. 42: 601-608, 1982. PubMed: 7034925
22757: Kim YW, et al. Characterization of clones of a human pancreatic adenocarcinoma cell line representing different stages of differentiation. Pancreas 4: 353-362, 1989. PubMed: 2734279
22758: Mullins TD, et al. Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines. Pancreas 6: 578-587, 1991. PubMed: 1946315
23087: Worlock AJ, et al. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res. 50: 7246-7251, 1990. PubMed: 2224857
|
|
ATCC® Number: CRL-1997? Price: $329.00
Designations: HPAF-II
Depositors: RS Metzgar
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: pancreas
Disease: adenocarcinoma
Cellular Products: mucin
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Antigen Expression: Blood Type A; Rh-; HLA A1, A10 (W34), B8, W22, Cw3
DNA Profile (STR): Amelogenin: X
CSF1PO: 10,11
D13S317: 12
D16S539: 11,13
D5S818: 11,13
D7S820: 10,13
F13A01: 5,17
F13B: 8,10
FESFPS: 11,12
LPL: 10
THO1: 9
TPOX: 8
vWA: 17
Age: 44 years
Gender: male
Ethnicity: Caucasian
Comments: HPAF-II is a human pancreatic adenocarcinoma cell line derived from peritoneal ascitic fluid of a 44 year old Caucasian male with primary pancreatic adenocarcinoma and metastases to the liver, diaphragm and lymph nodes. HPAF II is a spontaneous variant with unlimited replicative capability which proliferated from a static culture of HPAF-I cells.The cells express Muc 1 and Muc 4 mucin genes, and secrete high levels of Muc 1 mucin. They are pleomorphic and probably undergo some spontaneous differentiation in culture.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol:
1.Remove and discard culture medium.
2.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5.Add appropriate aliquots of the cell suspension to new culture vessels.
6.Incubate cultures at 37°C.
